Connect Biopharma Holdings Limited (NASDAQ:CNTB) Q2 2022 Results Conference Call September 13, 2022 4:30 PM ET

Company Participants

Ina McGuinness - IR

Dr. Zheng Wei - Co-Founder and CEO

Dr. Chin Lee - Chief Medical Officer

Steven Chan - CFO

Conference Call Participants

Louise Chen - Cantor Fitzgerald

Thomas Smith - SVB Securities

Kelly Shi - Jefferies

Joe Catanzaro - Piper Sandler

Operator

Good day and thank you for standing by. Welcome to Connect Biopharma First Half 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions]

I would now like to hand the conference over to your speaker for today, Ina McGuinness. You may begin.

Ina McGuinness

Thank you, operator. Today's call will be hosted by Connect Co-Founder and CEO, Dr. Zheng Wei; Chief Medical Officer, Dr. Chin Lee; and CFO, Steven Chan. Today's call is being webcast, and the replay will be available on the IR section of the Company's website for 12 months.

Following our prepared remarks, we'll open up the call to Q&A. Before we begin, let me remind you that during today's call, management will make various forward-looking statements. Investors are cautioned that these forward-looking statements are based on current expectations, and are subject to risks and uncertainties that could cause actual results or outcomes to differ materially from those indicated by our forward-looking statements.

Please read the safe harbor statement contained in the press release we issued earlier today as well as those contained in Connect Biopharma's registration statement on Form F1 for a more complete discussion of the risks and uncertainties.

Now, I'd like to turn the call over to Wei. Wei?

Dr. Zheng Wei

Thank you, Ina, and good day to all of those joining us today on the call and webcast. I plan to talk about the clinical progress we have made over the last six months, starting with our lead clinical candidate, CBP-201.

Turning to our trials to treat adult patients with moderate to severe atopic dermatitis, or AD. In the Phase 2b global CBP-201 trial, we reported 16-week data that met the primary and key secondary endpoints of the trial with favorable safety data. Additional analysis demonstrated a potentially competitive therapeutic profile for CBP-201 300 milligram administered every two weeks or every four weeks.

In the ongoing pivotal China-only trial for CBP-201 in AD, we received feedback from China Center for Drug Evaluation, or CDE, that led us to review the data from the first 255 patients already enrolled in our Stage 1 16-week treatment period. And if positive, review this data in a pre-BLA meeting with the CDE. This is particularly good news as this would potentially accelerate the time line to BLA submission of CBP-201 in China.